Prestige Biopharma participates in US gov’t Cancer Moonshot

It takes part in President Biden’s project to conquer cancer, with a pancreatic cancer drug candidate and diagnostic kit

Prestige Biopharma participates in US gov’t Cancer Moonshot
In-hyuk Park 1
Jul 18, 2023 (Gmt+09:00) hyuk@hankyung.com
Bio & Pharma

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US, announced on Tuesday that it will participate in the US government's cancer eradication project "Cancer Moonshot."

According to company sources, CancerX, a public-private collaboration established to drive the Cancer Moonshot, has selected Prestige Biopharma as a member, recognizing that its pancreatic cancer treatment strategy aligns with the project's goals.

The company explained that since CancerX publicly disclosed around 90 founding member companies last month, it has been actively enlisting additional companies in the field of cancer therapeutics.

Prestige Biopharma possesses drug candidates such as PBP1510 (ulenistamab), which neutralizes the gene PAUF (pancreatic adenocarcinoma up-regulated factor) excessively expressed in pancreatic cancer patients. Through this participation, the company plans to conduct various research related to pancreatic cancer diagnosis, treatment, and prevention utilizing PAUF concentrations.

The Cancer Moonshot was initially mentioned during the tenure of former US President Barack Obama, with the aim of national support for cancer prevention, early detection and the development of therapies. It is currently being pursued by President Joe Biden.

Write to In-hyuk Park at hyuk@hankyung.com
#Prestige BioPharma #Cancer Moonshot #CancerX #PBP1510 #PAUF #pancreatic cancer

Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation

Prestige Bio's pancreatic cancer treatment gets US FDA fast-track designation

Prestige Biopharma, a biopharmaceutical company in South Korea, announced on Thursday that their pancreatic cancer antibody drug, PBP1510 (Ulenistamab), has received fast-track designation from the US Food and Drug Administration.This designation enables clinical development and application pr

Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials

Prestige Bio's Herceptin biosimilar proves equivalence in clinical trials

Prestige Biopharma, a South Korean biopharmaceutical developer, said on Tuesday that the final analysis of phase 3 clinical trial on the anti-cancer biosimilar (biopharmaceutical generic drug) HD201 proved its equivalence to the original drug Herceptin.HD201 is Prestige Biopharma's first biosi

Prestige Biopharma submits clinical trial plan in Australia

Prestige Biopharma submits clinical trial plan in Australia

Prestige Biopharma, a Singapore-based biopharmaceutical company with operations in South Korea and the US,  has applied to the Australian clinical trial review committee for its phase 1 and 2a clinical trial plan of its new pancreatic cancer drug PBP1510 (ulenistamab).The company speciali

Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma attains patent for solid cancer treatment antibody

Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. The patent name is “Novel CTHRC1's specific antibody and use thereof."Following the PAUF (pancreatic adenocarcinoma up-regulated factor) neu